Stockwinners Market Radar for January 18, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EST Cathie Wood's ARK Investment bought 156.6K shares of Compass Pathways today

20:05 EST Cathie Wood's ARK Investment bought 50K shares of Tesla today

18:31 EST Inspirato announces plan to streamline operations - Inspirato announced a plan to streamline operations. The plan includes a workforce reduction, effective immediately, that impacts approximately 12% of the company's current staff. Moving forward, Inspirato's headcount consists of more than 800 dedicated hospitality professionals, an increase of over 300 employees compared to December 2020. "We took this step to help reduce costs as we manage Inspirato responsibly in the face of ongoing macroeconomic uncertainty," said Brent Handler, Inspirato's Co-Founder and Chief Executive Officer. "While we regret saying goodbye to this talented group of colleagues, we believe that the long-term opportunity for Inspirato remains strong. We believe this reduction will help us achieve our goal of Adjusted EBITDA breakeven in 2023 while continuing to deliver the service and certainty that our Inspirato subscribers expect whenever they travel with us." The company will provide further details when it reports financial results for the fourth quarter and full year 2022 later this year.

18:04 EST B2Gold sees 2023 total gold production topping 1M oz - The company sees "2023 total gold production guidance of 1,000,000 to 1,080,000 ounces, including 60,000 to 70,000 ounces of attributable production from Calibre and total consolidated cash operating cost guidance of $670 to $730 per gold ounce, slightly higher than the 2022 guidance range due to minor inflationary impacts from fuel, labour, and other key consumables."

17:53 EST Xpel director sells $1.42M in common stock - In a regulatory filing, Xpel disclosed that its director Richard Crumly sold 20K shares of common stock on January 13th in a total transaction size of $1.42M.

17:40 EST Officer of Akero Therapeutics Yale sells $253K in company shares - Office of Akero Therapeutics Catriona Yale disclosed in a filing that she had sold 5,000 shares of company stock at on January 13 at $50.53 per share, for a total transaction amount of $252,651.

17:30 EST Black Stone Minerals CFO Jeff Wood to leave company - Black Stone Minerals, L.P. announced that Jeff Wood, the President, Chief Financial Officer, and Treasurer of Black Stone's general partner, will leave the company effective February 28, 2023. Upon Mr. Wood's departure, Evan Kiefer, who currently serves as Vice President, Finance and Investor Relations, will assume the role of Interim Chief Financial Officer and Treasurer. Thomas L. Carter, Jr., Black Stone's Chief Executive Officer and Chairman commented, "Jeff has been an integral part of our management team and our success as a public company since he joined us in 2016, shortly after our initial public offering. He has brought a high level of professionalism to our organization and helped to navigate us through some difficult times, including Covid and the accompanying downturn in the commodity markets." Mr. Carter concluded, "On behalf of Black Stone's Board and senior management team, I want to thank Jeff for his contributions to the Company, which is today in one of the strongest financial positions in its history."

17:16 EST Vornado cuts quarterly dividend to 37.5c per share - The decrease is in recognition of the current state of the economy and capital markets and is reflective of Vornado's reduced projected 2023 taxable income, primarily due to higher interest expense. The dividend will be payable on February 10 to common shareholders of record on January 30.

17:04 EST EnLink Midstream raises quarterly dividend by 11% to 12.5c per share - The dividend will be paid on February 13, 2023, to unitholders of record on January 30, 2023.

17:01 EST Akoustis awarded first high-volume 5G mobile XBAW filter order - The company states: "Akoustis Technologies announced that it has received its first high-volume 5G mobile filter purchase order from its leading multi-billion-dollar Tier-1 RF component company customer. The filter is manufactured using the Akoustis XBAW process and is designed into the customer's new multiplexer product that is expected to ship in the first half of calendar 2023 as part of a major chipset OEM reference design. The filter solution leverages one of Akoustis' new wafer-level-packages, developed and manufactured in its Canandaigua, New York fab. The new XBAW(R)-based design is being used to address difficult coexistence issues between 5G mid-bands and Wi-Fi 6E 5 to 7 GHz bands. The customer is considering additional applications for filters using the XBAW(R) process in future modules for 5G smartphones and other mobile devices after the successful completion of this first solution."

17:00 EST PGT Innovations to partner with Corning on advanced window technologies - PGT Innovations (PGTI) "announce a first-of-its-kind collaboration with Corning (GLW) to produce next-generation glass technology beginning this year." CEO Jeff Jackson says: "Collaborating with Corning in the North American fenestration industry only furthers that position. Additionally, the technology advancements born from this collaboration directly support PGT Innovations' mission to continuously produce premium, high-quality products that enhance people's lives. We expect that the new glass technologies we will be able to offer consumers will change our industry and provide significant impact on home hardening, energy savings, and user comfort."

16:34 EST Advantage Solutions names Dave Peacock CEO succeeding Griffin - Advantage Solutions has named Dave Peacock chief executive officer and a member of its board of directors effective February 1. Advantage also appointed Chris Baldwin a member of Advantage's board of directors effective February 1. Peacock will succeed Jill Griffin, who resigned and has elected to pursue other business endeavors.

16:33 EST BHP Group affirms FY23 Iron Ore output view of 249MT-260MT - Affirms FY23 Copper output 1,635-1,825kt and metallurgical coal output of 29-32MT.

16:31 EST SQZ Biotechnologies receives continued listing standards notice from NYSE - SQZ Biotechnologies announced that on January 18, 2023, it received notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the company's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the company's common stock from the NYSE. The company plans to notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE's continued listing standards. Under NYSE rules, the company has a period of six months from receipt of the NYSE notice to cure the stock price deficiency and regain compliance with the NYSE's continued listing standards. The company can regain compliance at any time within such cure period if, on the last trading day of any calendar month during the cure period, the company has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. The company intends to consider available alternatives, including, but not limited to, a reverse stock split, subject to stockholder approval at the company's next annual meeting of stockholders, if necessary to cure the stock price deficiency. The company's common stock will continue to be listed and trade on the NYSE during this cure period, subject to SQZ Biotechnologies' compliance with other NYSE continued listing standards.

16:21 EST Bally's reducing current Interactive workforce by up to 15% - In a regulatory filing, Bally's Corporation disclosed that on January 18 the company announced a restructuring plan of the Interactive business intended to reduce operating costs and "continue the company's commitment to achieving profitable operations in its North American Interactive segment." The plan includes a reduction of the company's current Interactive workforce by up to 15%. "Decisions regarding the elimination of positions are subject to local law and consultation requirements in certain countries, as well as the company's business needs. The company estimates that it will incur between approximately $10M to $15M in cash severance costs in connection with the Plan, which the company expects to incur in the first quarter of 2023. The estimates of the charges and expenditures that the company expects to incur in connection with the plan, and the timing thereof, are subject to a number of assumptions, including local law requirements in various jurisdictions, and actual amounts may differ materially from estimates," the filing stated.

16:16 EST Oneok raises quarterly dividend 2% to 95.5c per share - The dividend is payable Feb. 14 to shareholders of record at the close of business Jan. 30.

16:13 EST Alcoa reports Q4 adjusted EBITDA $29M vs. $210M in Q3 - The company states: "Adjusted EBITDA excluding special items was $29 million, a decrease from the prior quarter due primarily to lower sequential prices for aluminum and alumina, higher raw material costs, and higher production costs. Also in the fourth quarter, the Company recorded a $25 million charge to cost of goods sold to establish an asset retirement obligation (ARO) for estimates of expected work on impoundments at the Alumar refinery in Brazil. Additionally, the Norwegian government recently approved an updated budget proposal that limits carbon dioxide compensation to be paid in 2023 based on 2022 power purchased and used in production. The unfavorable sequential impact is $35 million, which includes amounts previously accrued through September 30, 2022 and the absence of any accruals for the fourth quarter 2022."

16:12 EST M3-Brigade Acquisition III Corp. extends time to consummate initial combination - M3-Brigade Acquisition III, upon the request of its sponsor, M3-Brigade Sponsor III, has approved an extension of the period of time the company has to consummate its initial business combination by three months, from the current deadline of January 26, 2023 until April 26, 2023.The Sponsor, or its affiliates or designees will deposit an additional $1,696,500 into the company's trust account, in part from the company's working capital, for the benefit of the company's public stockholders. The company's stockholders are not entitled to vote on or redeem their shares in connection with the extension. The sponsor intends to request additional extensions of the period of time the company has to consummate its initial business combination, to the extent necessary to complete its previously announced business combination with Greenfire Resources. The charter permits a total of four three-month extensions, or until October 26, of which this is the second.

16:09 EST Chesapeake completes sale of initial Ford Eagle package or $1.43B - Chesapeake Energy has entered into an agreement to sell the Brazos Valley region of its Eagle Ford asset to WildFire Energy I for $1.425B. Chesapeake has agreed to sell approximately 377,000 net acres and approximately 1,350 wells in the Brazos Valley region of its Eagle Ford asset, along with related property, plant and equipment. Average net daily production from these properties was approximately 27,700 boe, 85% liquid, during 3Q22. As of December 31, 2021, net proved reserves associated with these properties were approximately 96.8 mmboe. Chesapeake expects the transaction to close in 1Q23. The company will receive $1.2B upon closing, subject to customary adjustments, with the additional $225M paid in yearly installments of $60M over the next three years and $45M in year four. Chesapeake anticipates the proceeds will be used to repay borrowings under its revolving credit facility and be available for its share repurchase program.

16:07 EST nCino appoints Greg Orenstein CFO - nCino announced the appointment of Greg Orenstein as nCino's CFO. Orenstein will succeed David Rudow, who will be leaving the company effective January 31. Orenstein has leadership experience at nCino, having joined the company in 2015, and most recently serving as its Chief Corporate Development & Strategy Officer. Prior to that, he served as nCino's Chief Corporate Development & Legal Officer and Secretary.

16:07 EST Kinder Morgan authorizes $1B share buyback - On January 18, the Kinder Morgan board of directors approved an increase in KMI's share repurchase authorization from $2.0B to $3.0B.

15:19 EST NuZee trading resumes

14:58 EST Union Bankshares raises dividend 2.9% to 36c per share from prior 35c - Union Bankshares announced results for the three months and year ended December 31. Net income was $3.4M and $12.6M for the three months and year ended December 31 resulting in earnings per share of 77c and $2.81 for the same periods, respectively. The Board of Directors also declared a cash dividend of 36c per share for the quarter, an increase of 2.9% from the cash dividend of 35c paid in recent prior quarters, payable February 2 to shareholders of record as of January 28.

14:03 EST Archer Aviation CFO Mesler acquires 202,000 class A shares - In a regulatory filing last night, Archer Aviation CFO Mark Mesler disclosed the purchase of 20,000 class A common shares of the company on January 13 at a price of $2.6306 per share.

14:02 EST Archer Aviation director Diaz acquires 19,322 class A shares - In a regulatory filing last night, Archer Aviation director Fred Diaz disclosed the purchase of 19,322 class A common shares of the company on January 12 at a price of $2.5876 per share.

13:57 EST NAMS Stock trading resumes

13:35 EST North American rail traffic up 0.6% for the week ending January 14 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending January 14. For this week, total U.S. weekly rail traffic was 486,000 carloads and intermodal units, down 1.7% compared with the same week last year. Total carloads for the week ending January 14 were 244,171 carloads, up 4.2% compared with the same week in 2022, while U.S. weekly intermodal volume was 241,829 containers and trailers, down 7% compared to 2022. Seven of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included grain, up 3,483 carloads, to 28,008; nonmetallic minerals, up 3,033 carloads, to 30,380; and motor vehicles and parts, up 2,176 carloads, to 14,562. Commodity groups that posted decreases compared with the same week in 2022 were chemicals, down 2,226 carloads, to 31,793; forest products, down 715 carloads, to 9,244; and miscellaneous carloads, down 117 carloads, to 9,580. North American rail volume for the week ending January 14,on 12 reporting U.S., Canadian and Mexican railroads totaled 350,991 carloads, up 7.5% compared with the same week last year, and 319,854 intermodal units, down 6% compared with last year. Total combined weekly rail traffic in North America was 670,845 carloads and intermodal units, up 0.6%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP),Greenbrier (GBX), Trinity Industries (TRN), FreightCar America (RAIL), and Wabtec (WAB). Reference Link

12:34 EST Sony says 'Returnal' PC port to release February 15 - Sony announced that the PC port of its 2021 PlayStation 5 exclusive title "Returnal" will release on February 15, 2023. "NVIDIA DLSS and AMD FSR have been added, allowing you to dial up your framerate without compromising on resolution," said Mikael Haveri, brand director at "Returnal" studio Housemarque, which is owned by Sony. "NVIDIA NIS has also been added for those players who also want to see an increase in performance, but don't have the hardware to support DLSS or FSR. Returnal also supports ray-traced shadows as before, but now our friends at Climax Studios have added the support for RT reflections as well. This will make the contrast of a dark setting and neon bullets pop out even more than before. All of this can be now seen in two new wide resolution formats, Ultrawide at 21:9 and Super Ultrawide 32:9. Think of all of that screen real estate that you will be able to take in when you're not in the middle of a giant boss fight." Reference Link

12:05 EST NuZee partners with Malu on specialty single serve coffees - NuZee announces a new partnership with Malu, a specialty coffee company that creates unique blends of single-serve coffee. After months of sourcing and experiments, Malu now offers high-quality specialty coffee blends. NuZee maximizes these blends with innovative, eco-friendly, single-serve pour-over pouches.

12:00 EST Chegg falls -14.9% - Chegg is down -14.9%, or -$3.65 to $20.80.

12:00 EST Valens Semiconductor rises 8.6% - Valens Semiconductor is up 8.6%, or 43c to $5.42.

12:00 EST Energy Vault rises 37.7% - Energy Vault is up 37.7%, or $1.34 to $4.90.

11:52 EST Alvarium Tiedemann Holdings Inc trading resumes

11:44 EST 22nd Century enters distribution partnerships with Core-Mark, Eby-Brown - 22nd Century Group announced new distribution partnerships with Core-Mark International and Eby-Brown Company. 22nd Century's VLN products are now available for purchase by eligible Core-Mark and Eby-Brown customers as a part of 22nd Century Group's state and regional rollout program.These new partnerships provide nationwide distribution capabilities for VLN via 31 Core-Mark and Eby-Brown warehouses. Additionally, 22nd Century will attend 11 regional trade shows sponsored by the distributors in 2023 providing 22nd Century with the opportunity to introduce VLN to thousands of Core-Mark and Eby-Brown's independent retail and chain store operators.

11:33 EST Inter&Co announces '60-30-30' long-term growth targets - Inter&Co announced at its 2023 Investor Day its "60-30-30" growth targets. Inter revealed its ambitious targets for the next five years as it continues to implement its strategy, grow its Super App, expand into new markets and leverage its comparative financial advantages. By year-end 2027, Inter expects to: Achieve strong scale, more than doubling its current client base to 60 million clients; Operate more efficiently than its peers, with a target efficiency ratio of approximately 30%; Deliver high profitability, generating more than R$5 billion in net income with a R$100 billion loan book, bringing return on equity to approximately 30% "Inter has gone beyond banking to become the premier Super App in the Americas. By balancing the right combination of technology investment with unit economic growth and profitability, we have built a suite of capabilities that are unmatched in the market," said Joao Vitor Menin, CEO of Inter&Co. "We are still in the early stages in our evolution, but our impressive results showcase how we are taking Inter to the next level. We are confident that we have the right strategy, solutions and team in place to execute on our goals and deliver sustainable growth."

11:18 EST Linde shareholders approve proposal to delist from Frankfurt Stock Exchange - Linde announced its shareholders have approved the company's proposal for an intercompany reorganization that will result in the delisting of its ordinary shares from the Frankfurt Stock Exchange. Preliminary voting results indicate that at least approximately 93% of the votes cast on each of the delisting proposals were cast in favor at the Court Meeting and the Extraordinary General Meeting of Shareholders held today. The total number of votes cast represented approximately 78% of total Linde plc shares outstanding. Following the completion of legal and regulatory approvals, Linde anticipates that the intercompany reorganization and delisting process will be completed, and its ordinary shares will be delisted from the Frankfurt Stock Exchange, on or about March 1, 2023. In connection with the closing of the intercompany reorganization, Linde shareholders will automatically receive one share of the new holding company, to be listed on the New York Stock Exchange in exchange for each share of Linde plc they own. The new holding company will also be named "Linde plc" and will trade under the existing ticker "LIN".

11:05 EST United: Booked revenue for second half of Feb., March 30%-40% above 2019

11:04 EST United sees taking delivery of 92 737 Maxs, 2 787s, 4 A321Neos in 2023

10:58 EST United Airlines sees 'positive' adjusted free cash flow for 2023

10:43 EST United CEO: 'You can't run your airline like it's 2019 or you will fail'

10:40 EST United Airlines CEO: What happened over holidays 'wasn't one-time event' - "We need 10% more pilots and 5% more aircraft just to produce the same number of ASMs" as before the pandemic, says CEO Scott Kirby.

10:34 EST United Airlines CEO: Ample evidence of structural changes in the industry - Comments taken from Q4 earnings conference call.

10:28 EST Teladoc cuts 6% of workforce in restructuring - In a regulatory filing earlier, Teladoc Health disclosed that on January 18 the company announced a restructuring plan intended to reduce operating costs. In addition, the company underwent certain other cost-saving actions taken during the latter part of the fourth quarter of 2022. The combination of these actions results in a reduction of the company's workforce of approximately 6%, and office space reductions within certain markets. "The fourth quarter actions did not have a material impact on 2022 financial operating results. Decisions regarding the elimination of positions are subject to local law and consultation requirements in certain countries, as well as the company's business needs. In conjunction with earlier cost-saving actions, the company incurred approximately $4.4M in pre-tax charges in the fourth quarter of 2022, consisting of approximately $2M in costs related to employee transition, severance payments, employee benefits, and related costs, and approximately $2.4M in exit costs associated with the office space reductions. In connection with the restructuring plan, the company expects to incur approximately $17M in pre-tax charges in 2023, consisting of approximately $9M substantially related to employee transition, severance payments, employee benefits, and related costs expected to be realized in the first quarter of 2023, and approximately $8M of exit costs associated with office space reductions expected to occur by the second quarter of 2023. Of the aggregate amount of pre-tax charges that the company estimates it will incur in 2023, approximately $10M are expected to result in future cash expenditures related to the workforce reductions. In addition to these charges, the company expects a reduction in stock-based compensation of approximately $6M in the first quarter of 2023 associated with forfeited stock awards," the filing stated.

10:20 EST AMTD Digital Inc - ADR trading resumes

10:11 EST Campbell Soup: No commercial roles being eliminated related to office closings

10:10 EST Apple announces HomePod 2nd generation, available February 3 - Apple announced HomePod 2nd generation, which it calls "a powerful smart speaker that delivers next-level acoustics in a gorgeous, iconic design." The new HomePod is available to order online and in the Apple Store app for $299 U.S. starting today, with availability beginning Friday, February 3. Reference Link

10:09 EST Delta Air Lines executes options for 12 new Airbus A220-300 aircraft - Delta Air Lines (DAL) said in a statement that it will continue refreshing its fuel-efficient, state-of-the-art fleet after executing options for 12 new Airbus (EADSY) A220-300 aircraft. Slated for delivery in 2026 and 2027, the expansion of Delta's A220 family is "an important step towards the airline's ongoing efforts on fleet simplification, while investing in more sustainable aircraft that provide a best-in-class customer experience," the airliner said. "These 12 additional A220 aircraft will help power our increasingly streamlined fleet while also providing our customers with the elevated in-flight experience they've come to expect from Delta," said Kristen Bojko, Vice President of Fleet. Powered by Pratt and Whitney's latest-generation geared turbofan GTF engines, the A220 offers 25% better fuel efficiency than retiring aircraft in its class. Delta currently has 14 A220-300s in service and 60 on order, including the 12 options exercised on Wednesday. In addition, Delta currently operates a fleet of 45 109-seat A220-100 aircraft. Delta took delivery of its first Airbus A220 in October 2018 and was the first U.S. carrier to operate the aircraft type. Reference Link

10:03 EST IZEA launches IZEA Flex influencer marketing platform - IZEA Worldwide announced it has launched IZEA Flex, its next-generation, comprehensive influencer marketing platform built for brands and agencies of all sizes. First announced during IZEA's "SUPERCHANGED" streaming event, IZEA Flex is a data-centric suite of marketing tools that allow users to track, customize and export relevant data, from creator profiles to campaign metrics. The tools in IZEA Flex are powerful on their own, but when tied together, empower marketers to manage and optimize influencer marketing campaigns and strategies at an enterprise level.

10:00 EST Global Blue falls -6.4% - Global Blue is down -6.4%, or -35c to $5.12.

10:00 EST Chegg falls -10.5% - Chegg is down -10.5%, or -$2.58 to $21.86.

10:00 EST Archer Aviation rises 19.7% - Archer Aviation is up 19.7%, or 51c to $3.09.

09:48 EST WeWork, Captivate enter strategic partnership for digital content, advertising - Captivate announced its strategic partnership with WeWork to transform existing digital screens in WeWork lobbies, elevator banks and communal workspaces to display the Captivate on-screen content experience. "WeWork Powered by Captivate" will give advertisers access to high-value, modern professionals who make both business and personal purchase decisions.

09:47 EST Global Blue falls -6.4% - Global Blue is down -6.4%, or -35c to $5.12.

09:47 EST New Oriental Education rises 7.6% - New Oriental Education is up 7.6%, or $2.85 to $40.38.

09:47 EST Energy Vault rises 16.0% - Energy Vault is up 16.0%, or 57c to $4.13.

09:36 EST Hutchmed announces inclusion of ORPATHYS in China's NRDL - HUTCHMED (HCM) announces, following negotiations with the China National Healthcare Security Administration, ORPATHYS has been included in the updated National Reimbursement Drug List for the treatment of locally advanced or metastatic non-small cell lung cancer adult patients with MET exon 14-skipping alterations who have progressed after or unable to tolerate platinum-based chemotherapy. The updated NRDL will take effect from March 1, 2023. Savolitinib, marketed in China under the brand name ORPATHYS, is an oral, potent and highly selective MET tyrosine kinase inhibitor jointly developed by AstraZeneca (AZN) and HUTCHMED with HUTCHMED taking the lead in China, and commercialized by AstraZeneca worldwide.

09:29 EST PNC Financial expects to continue share repurchases at 'reduced rate' vs. 2022

09:21 EST Fat Projects confirms funding to extend period to consummate combination - Fat Projects Acquisition announced the deposit of an aggregate of $312,899.94 into the Company's trust account, which came from cash on hand of the Company and from proceeds of loans from shareholders of the Company's Sponsor and other designees of the Company who received non-interest bearing, unsecured promissory notes in consideration for the loans and which enables the Company to extend the period of time it has to consummate its initial business combination by one month from January 15, 2023 to February 15, 2023. The Extension is the first of up to six one-month extensions permitted under the Company's governing documents. The Extension provides the Company with additional time to complete its initial business combination with Avanseus Holdings Pte. Ltd., a Singapore private company limited by shares. As previously reported, FATP and Avanseus entered into a Business Combination Agreement dated August 26, 2022, as amended by a First Amendment to Business Combination Agreement dated October 3, 2022, that provides for a series of transactions, pursuant to which, among other things, Avanseus' shareholders will exchange all of their outstanding Avanseus shares in consideration for newly issued FATP Class A Ordinary Shares, subject to the conditions set forth in the Business Combination Agreement, with Avanseus thereby becoming a wholly owned subsidiary of FATP. In connection with the Business Combination, FATP will change its corporate name to "Avanseus Holdings Corporation". The Charter Amendment and Trust Agreement Amendment and the first extension described above will provide FATP and Avanseus with additional time to complete the Business Combination.

09:19 EST Hepion announces results from preclinical studies of rencofilstat - Hepion Pharmaceuticals announced results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma. Rencofilstat exerted anti-cancer activity across a large panel of MM cell lines, and most potently, in combination with bortezomib, a proteosome inhibitor and first-line treatment for MM. These results strengthen Hepion's oncology initiatives and further support rencofilstat's poly-indication potential. The combination of rencofilstat and bortezomib produced 100% cytotoxicity in cell culture experiments across all 16 MM cell lines, including three lines that are characterized as bortezomib-resistant. The cytotoxic activity of rencofilstat plus bortezomib was synergistic in every cell line, showing greater cytotoxicity in combination than the sum of the two drugs individually. Rencofilstat administered individually resulted in reduced cell numbers in most cell lines, and the suppressive effect of rencofilstat correlated to reduced gene expression levels of cyclophilins A and D, two of the known targets of rencofilstat. Most of the experiments were performed by Diag2Tec, a contract research organization with expertise in MM. These results were consistent with an independent study that reported that cyclophilin A inhibition should be considered as a therapeutic strategy for resistant MM.1 They were also similar to recent studies showing that a combination of rencofilstat and another proteosome inhibitor, ixazomib, synergistically killed prostate cancer cells. Together, they provide strong rationale for considering a rencofilstat-proteosome inhibitor combination for clinical investigation in MM or other cancers.

09:18 EST CNH Industrial takes minority stake in EarthOptics, terms not disclosed - CNH Industrial announces a minority investment in the US-based ag tech company EarthOptics through its Ventures arm. EarthOptics' proprietary sensor technology precisely measures the health and structure of soil through a combination of ground-based sensors, satellites, physical soil samples, machine learning models and agronomic expertise. By providing such a wide range of soil data, this technology enables farmers to better manage their land and enhance its value. Insights can help them drive multiple improvements from increasing crop yield to reducing fertilizer application, and assessing their farm's carbon impact, to name a few key areas. This funding - part of EarthOptics' Series B investment round - will help to further build out their sensor suite's hyper-accuracy capabilities to boost acreage growth and bring greater savings. It will also allow the company to scale cooperation with service providers for data insights. CNH Industrial will begin a pilot testing phase of EarthOptics' soil sensing technology through our Case IH brand in 2023. Commercial plans will be the subject of future announcements. The goal of this technology is to accelerate our work in tillage automation and provide greater agronomic insights for customers.

09:17 EST Pokemoto opens two new locations in Connecticut - Pokemoto announced that it has opened two new locations in Connecticut, the market of origin for the brand. Berlin, Connecticut and Guilford, Connecticut both recently opened bringing the number of Pokemoto locations in Connecticut to 18. With these two Connecticut openings, Pokemoto now has 29 currently open locations and an additional 45 franchise locations sold but not yet opened covering 16 states.

09:15 EST REV Fire Group partners with Daytona International Speedway - REV Fire Group, which includes REV Group manufacturers of E-ONE, KME, Ferrara, Spartan Fire Chassis, Spartan Emergency Response, Smeal, and Ladder Tower fire apparatus brands, announces its all-electric Vector fire truck is one of four REV Fire pumpers that will be part of the firefighting fleet used at Daytona International Speedway in 2023. The zero emission and zero greenhouse gas Vector fire apparatus aligns with Daytona International Speedway sustainability initiatives, including a project to plant more than 100 trees within view of the track's grandstands in April 2022. Similar initiatives championed by NASCAR and its partners include a blended biofuel, in-venue recycling efforts, and the recycling of racing oils and race-used tires. "We are excited to provide the all-electric Vector for our Florida neighbor, Daytona International Speedway, to protect its employees, NASCAR drivers and the many fans and spectators who attend "The Great American Race" and other events," said Mike Virnig, Vice President of the REV Fire Group, which is headquartered in Ocala, Fla. "Vector also protects the environment, making this a perfect collaboration with DIS and NASCAR and their many green initiatives designed to reduce the track and sport's carbon footprint and promote sustainability."

09:13 EST EnWave signs commercial license with Canadian cannabis company - EnWave signed a royalty-bearing commercial license agreement with an undisclosed, major Canadian cannabis company. Pursuant to the License Agreement, the Cannabis Partner has been granted the non-exclusive right to use EnWave's proprietary Radiant Energy Vacuum dehydration technology to produce cannabis products in Canada. The Cannabis Partner has also acquired a 120kW REV machine, which it intends to use for the production of premium smokeable flower, cannabis plant material destined for extraction and several edible products. EnWave will hopefully install and commission this machine at the Cannabis Partner's facility in a shorter time period than normal, as the Machinery has been fully fabricated and is ready for deployment. The Machinery was purchased back from a U.S. cannabis licensee of EnWave whom satisfied all payment obligations, but never took possession of the equipment due to operational challenges. The amount paid to acquire the machinery from the U.S. cannabis licensee for re-sale allows for EnWave to realize a margin comparable to the margin that would be recognized from the manufacture and sale of a new 120kW REV machine. Concurrent with the buyback of the Machinery, the U.S. cannabis licensee and EnWave mutually agreed to terminate the license agreement held between the two entities.

09:12 EST Verisk Analytics announces Hail Impact Energy, Tornado Probability solutions - Insurance professionals can now get highly detailed, real-time data about the impact of hail and tornadoes with Verisk's latest weather enhancements, Hail Impact Energy and Tornado Probability. Hail Impact Energy estimates the total energy of hail when it hits a surface and incorporates Verisk's existing Respond hail products that account for hail size, duration, and probable severity. Tornado Probability provides a highly granular first look at where tornadoes likely hit by leveraging horizontal and vertical radar pulses. Both products are updated every 5 - 10 minutes.

09:11 EST Veris Residential forms strategic partnership with the MIT - Veris Residential announced that it has formed a strategic partnership with Massachusetts Institute of Technology's, or MIT) Center for Real Estate, one of the world's foremost institutes for the study of real estate and technology. As a Strategic Partner, Veris Residential will work closely with MIT/CRE to research, develop, and implement innovative solutions for advancing and optimizing multifamily real estate operations. In addition, Veris Residential today formally announced the launch of The Veris Innovation Lab. The Lab, which was established in summer 2022, will work closely with MIT/CRE's worldwide network of alumni, researchers, affiliates, and industry partners to study real-world challenges in multifamily real estate and aim to devise novel solutions that can be adopted by multifamily owners, operators, and developers.

09:09 EST GSE Systems awarded new contract by US Government engineering laboratories - GSE Solutions announced a new contract for the expansion of specialized support services to two US Government engineering laboratories dedicated to the support of the US Navy. GSE will continue to serve as a subcontractor to a large global engineering, construction, and project management firm that has the master contract for managing the labs. GSE will provide Engineering services that include simulation engineers and test specialists to support simulation-based training systems. The contract was awarded in January, and the initial year of the contract is worth $5.47M, which will go into the backlog and take effect on February 1. The contract includes additional options for the subsequent four years that, if exercised, would bring the total value to approximately $28.3M over five years. GSE has been under a series of service contracts with these laboratories for 21 years and has been tasked to build and test training systems used across a number of government locations in support of the US Navy.

09:09 EST Correct: Evercore price target not changed at Needham

09:09 EST Beacon adds locations to support more Texas contractors - Beacon announced that it has opened greenfield locations in Baytown and suburban Forth Worth, Texas. The Baytown branch extends service in the greater Houston market, reaching across Harris and Chambers counties and the Galveston Bay region. The branch on Fort Worth's western side is at the busy crossroads of Highways 820 and 30. "These new branch locations were chosen specifically to support our customer contractors who work near the major Fort Worth and Houston markets. Both new branches are stocked with leading brands of residential and commercial roofing and complementary products, including Beacon's own TRI-BUILT products," commented Peter Lippert, Beacon's Regional Vice President, Texas. "We are pleased to expand Beacon's service in Texas, where we now have 34 branches across the state and offer online business tools like our leading digital platform, Beacon PRO+."

09:07 EST Upexi announces Amazon.com approval for Tytan Tiles brand - Upexi (UPXI) announced the Company's children's toy brand, Tytan Tiles, has officially been approved by Amazon.com (AMZN) to launch its first branded direct-to-consumer storefront, Tytan Brands Store, for its top selling toy products. Additionally, Tytan Tiles has officially launched, as previously announced, into over 2,000 Walmart storefronts nationally. ytan Tiles is a toy company that has grown 100% year-over-year for the past two years, driven by its line of STEM toys.

09:07 EST The Hartford appoints Dominioni head of sales, underwriting - The Hartford has appointed Hank Dominioni head of sales and underwriting for its Middle and Large Commercial Businesses' Northeast Division. In his new role, Dominioni will be responsible for leading sales and underwriting operations for the company's independent agents, brokers and customers across seven Northeastern states from Maine to New York. He will report to Gretchen Thompson, head of Field Operations and General Industries for Middle and Large Commercial insurance.

09:05 EST Weber announces new product offerings for 2023 season - Weber announced its innovative new product offerings for the upcoming 2023 barbecue season. "Our product teams continue to push the boundaries of high-performance outdoor cooking in fuel and product categories that home cooks have just started to explore, including electric, griddle, and pellet grilling," said Mike Jacobs, Chief Operating Officer of Weber. "To develop this year's product portfolio, we spent hundreds of hours talking to and cooking with people to determine how our products could help them more fully enjoy coming together around the grill. As a result, this line-up redefines what's possible when cooking outside by enabling our owners to create delicious new meal options, express their creativity, cook with greater ease, control, and predictability, and simplify clean up."

09:05 EST Avidity granted FDA Fast Track designation for AOC 1020 - Avidity Biosciences announced that the FDA has granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy, or FSHD. FSHD is a serious, rare, hereditary muscle-weakening condition marked by life-long, progressive loss of muscle function that causes significant pain, fatigue, and disability. AOC 1020 is being studied in the Phase 1/2 FORTITUDE clinical trial in adults with FSHD and is the company's second muscle-targeting small interfering RNA, or siRNA, AOC in clinical development. Avidity plans to share data from a preliminary assessment of AOC 1020 in approximately half of study participants from the FORTITUDE trial in the first half of 2024. Fast Track designation enables more frequent interactions with the FDA to expedite the development and review process for drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Currently, there are no FDA-approved treatments for people living with FSHD. Avidity has three distinct rare disease programs in the clinic. In addition to AOC 1020, the company is also evaluating AOC 1001 in the Phase 1/2 MARINA and MARINA open-label extension clinical trials for the treatment of myotonic dystrophy type 1 and AOC 1044 in the Phase 1/2 EXPLORE44 trial for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping.

09:04 EST Jowell Global reports 2022 diamond sales over $1.78M - Adamas One announced financial results for the fiscal year ended September 30, 2022. Financial highlights from the year, which are discussed in detail in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on January 13, 2023, include more than $1.78 million in sales of the Company's Lab-Grown Diamonds, compared to zero sales in the prior fiscal year. Significantly, based on the Company's preparations and refinement of its processes, sales and marketing activities began mid-second quarter, which means that all sales were achieved within the closing seven months of the year. Other pertinent activities include the initial public offering of the Company and significant intellectual property activities. "Our goal as a company is continued growth, quarter over quarter, year over year," stated Adamas One CEO, Jay Grdina, "Fiscal 2022 was important for the Company as we pivoted from our R&D efforts to production for commercial sales of our diamond products. We are now hard at work both producing diamonds and upgrading our production capabilities, working diligently to reach full capacity at our Greenville, S.C. facility. We are on target to have our Greenville facility at full manufacturing capabilities of 3,000 cts per month, and expect over $1M in revenue per month, both by May 2023. All of these activities are designed to lay the groundwork for what we believe will be a successful fiscal 2023. We look forward to, as appropriate, continuing to update our shareholders on our progress."

09:01 EST Freddie Mac Multifamily reports 2022 production volume totaled $73.8B - Freddie Mac Multifamily's 2022 production volume totaled $73.8 billion, including a record of nearly $1 billion in Low-Income Housing Tax Credit equity investments. The agency also increased its targeted affordable loan purchases for properties that have a regulatory rent restriction or subsidy by close to 60% to a record $15.3 billion in 2022, up from $9.6 billion in 2021. "In a year marked by record rent inflation and a rental housing supply crisis, Freddie Mac Multifamily prioritized its affordable housing mission," said Kevin Palmer, head of Freddie Mac Multifamily. "Not only did we exceed our aggressive affordable housing goals, but we also set a record for Targeted Affordable Housing, ramped up our LIHTC equity investments by 45% and made nearly $2 billion in forward commitments designed to bolster future housing supply."

08:52 EST 8x8 announces approximately 7% reduction in workforce - In a regulatory filing, 8x8 announced a restructuring intended to focus resources on targeted market opportunities, reduce operating costs, improve operating margins, and continue advancing the company's ongoing commitment to increasing levels of non-GAAP profitability and cash flow. The restructuring includes a reduction of the company's current workforce by approximately 7% globally. Decisions regarding the elimination of positions are subject to local law and consultation requirements in certain countries, as well as the company's business needs. The actions associated with this reduction in workforce are expected to be substantially complete by the end of the company's first quarter of fiscal 2024 ending June 30, 2023, subject to local law and consultation requirements.

08:49 EST BriaCell receives agreement, feedback from End of Phase II meeting with FDA - BriaCell Therapeutics received agreement and positive feedback from its End of Phase II meeting with the FDA regarding BriaCell's lead clinical candidate, Bria-IMT in combination with a checkpoint inhibitor, in advanced metastatic breast cancer. BriaCell and the FDA have agreed on the primary end point, the essential elements of the study design, and the type of patients to be enrolled in BriaCell's upcoming pivotal clinical study. This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist. Registration study success could lead to a Biologics License Application submission for the approval of the combination regimen for commercialization in advanced metastatic breast cancer.

08:47 EST enVVeno Medical appoints Hamed Alavi as SVP, CTO - enVVeno announced the promotion of Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer. Alavi joined enVVeno Medical as Director, Research, Development and Quality in July 2020 and was promoted to Vice President of Research, Development and Quality in January 2021. In his new role as CTO, Dr. Alavi will seek to incorporate of innovative technologies such as artificial intelligence and cloud-based computing into our existing product mix, while also preparing our manufacturing and quality departments for commercialization of the VenoValve.

08:45 EST Evoke abstract accepted at AMCP meeting - Evoke Pharma announced that its abstract entitled "Real-World Healthcare Resource Utilization of Patients Treated with Metoclopramide Nasal for Diabetic Gastroparesis DGP will be presented at the Academy of Managed Care Pharmacy AMCP annual meeting taking place in San Antonio, TX from March 21-24. Lead author, Dr. David C. Kunkel, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health, emphasized the challenges faced by patients with gastroparesis who have limited treatment options and often experience flare-ups. "The positive response to the clinical utilization of GIMOTI gathered from patients through our studies and surveys is highly encouraging and continues to emphasize the major treatment gap GIMOTI fills every day for people suffering from diabetic gastroparesis. Patients and health care providers need new treatment options and are eager to learn whether these options can improve their symptoms and reduce their need to visit the ER or take more invasive steps to improve their condition. The presentation at the AMCP meeting will show how GIMOTI utilization is supporting the continuum of care for patients," commented Chris Quesenberry, Chief Commercial Officer for GIMOTI.

08:43 EST Siyata Mobile receives follow-on orders fro UV350 device - Siyata Mobile announced it has received follow-on orders from an existing customer for its Uniden UV350, a 4G/LTE all-in-one in-vehicle communication device. "These orders, which total approximately $400,000, will be used to equip an expanding fleet of emergency response vehicles with our high-performing UV350 devices," said Marc Seelenfreund, Siyata CEO. "Importantly, these follow-on orders are a strong testament to the value our devices are providing for first responders and the strength of our relationship with this operator. Since 2019, this customer has invested more than $1.7 million in our UV350 and related accessories."

08:40 EST Nauticus begins international expansion with operating bases in Norway and UK - Nauticus Robotics announced the initiation of its operations in Norway and the United Kingdom, beginning the Company's international expansion strategy for 2023 and beyond.The operating bases are strategically located in Stavanger, Norway and Aberdeen, Scotland to service the North Sea offshore market. The Company will deploy assets and collaborate with local partners to service the region's extensive offshore wind and oil and gas assets with its expanding Nauticus Fleet, a robotic navy of surface and subsea robots. These regional bases will provide local subject matter expertise and logistics as the Company's international operations continue to grow. Eventually, Nauticus plans to open bases around the world, strategically located in targeted growth markets and equipped with local remote operation centers and service teams.

08:37 EST Arcimoto announces pricing of $12M public offering - Arcimoto announced the pricing of its previously announced public offering of 4,000,000 shares of common stock and warrants to purchase up to 4,000,000 shares of common stock at a combined purchase price of $3.00 per share and accompanying warrant for aggregate gross proceeds of approximately $12 million, before deducting placement agent fees and other offering expenses. The warrants to be issued will have a five-year term, will be exercisable immediately, and will have an exercise price of $3.00 per share. The closing of the offering is expected to occur on or about January 20, 2023, subject to the satisfaction of customary closing conditions. We intend to use the net proceeds from the offering for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

08:37 EST Horizon Bancorp announces Thomas Prame to be appointed CEO June 1 - Horizon Bancorp announced that Thomas M. Prame will be appointed the Chief Executive Officer of both organizations effective June 1. Craig M. Dwight, will retain the title of Chief Executive Officer until June 1st and retire as an employee from Horizon and Horizon Bank effective July 3. Mr. Dwight will remain the Chairman of the Board of both organizations. Prame will continue in his role as President of both organizations. Mr. Dwight has served Horizon as its Chief Executive Officer since 2001 and Chairman since 2013. Prior to that, he was the President and Chief Administrative Officer of Horizon and the Chief Executive Officer and Chair of Horizon Bank commencing in 1998. Mr. Dwight has also served on the Board of Directors of Horizon and Horizon Bank since 1998 and will continue to serve as Chairman of both organizations.

08:36 EST Herborium Group provides shareholder update on 2022 accomplishments - The letter read in part, "As the most difficult two years in a history of our Nation, communities and businesses, marked by Covid pandemic can finally be seen in the rear mirror we are collectively facing new challenges and new opportunities both in the USA and on the world stage. This is why I feel it is important to provide a separate update on the 2022 and Corporate Milestones we achieved, and than -in a separate document share our plans, strategies and opportunities for 2023 and beyond. We at Herborium feel that in a world full of uncertainties it is appropriate to share updates on the solid foundation we built to enable the Company to adapt to the changing environment encountered in 2022, and to secure our ability to evolve and grow to assure continuous increases in shareholders value. In Shareholders Update Part 2 we will present our plans for 2023. 2022 Milestones: Keeping The Course: Despite the disruptions and dislocations caused by the Covid epidemic, Herborium was able to not merely survive but actually advance its programs during these challenging times. We harnessed two major trends resulted from the pandemic that are here to stay: the growing use of technology in all aspects of life including healthcare, wellness and beauty, growing interest in natural, holistic and integrated approach to all aspects of healthcare. These values have been represented by and powered Herborium's Mission since the Company's inception. Growing Revenues: Herborium's financial results improved. Our revenues grew 8.5% in comparison to 2021 surpassing the $1 Million threshold. All four quarters this year were profitable thanks to further reduction in the operational costs. No Dilution: Furthermore -the growth was self perpetuated without any further dilution. Debt Reduction: Company's efforts to reduce debt was achieved by over $110,000 in retired friendly Notes. As a micro-cap company this prevented the issuance of hundred of millions of new shares. Company Ranking: In 2022 Herborium was the subject of a positive Research Report by the Independent Financial Analyst . In addition, HBRM has been classified as the highest tier company on OTC and has been qualified among the most desirable trading tickers on OTC due to its historical and continued commitment to compliance, ease of electronic stock management and clean regulatory records.New Products: As a part of our commitment to continue to satisfy consumer needs and improve profitability - the Company commenced a complicated process of developing a second generation of AcnEase its lead acne and Rosace Botanical Therapeutic. We expect to complete this process in 2023. This next generation, all natural product should provide for more convenient pattern of use, lower cost and broader application options. Entering the Artificial Intelligence: Medical, Wellness and Beauty Space: As Covid Pandemic accelerated some specific healthcare, consumer and technology trends, specifically the personalization and individualization of information, diagnosis and advisement as well as marketing use of AI technology, Herborium enter this space in 2022 through partnering with ADRECOM INC. an innovative, multinational technology group specializing in developing propriety AI technologies to create a muti-faced, proprietary AI marketing and counseling platform in the space of skin health, wellness and beauty focus on the natural medicinal ingredients and know how. The first stage of designing this platform was completed and is ready for launch and testing in 2023. ESG: 2022 saw a further increased focus on the 'environmental, social, and governance' movement, though this far from new to us here at Herborium. As a woman-led company offering natural, environmentally sustainable solutions that provides value for a diverse group of stakeholders, 'ESG' has always been part of our 'DNA'. Investors Relations : We have marked 2022 by more tweets , press releases and on going communication with Shareholders that in the previous years. As there is always place for improvement, we are certainly committed to further improve those efforts in 2023."

08:34 EST HeartCore Enterprises announces sixth and seventh Go IPO agreement - HeartCore Enterprises, announced that it has signed an agreement with BloomZ and a Japanese healthcare company for its sixth and seventh Go IPO consulting service win. As part of the Consulting Agreement, HeartCore will assist BloomZ and the healthcare client in its efforts to go public and list on the Nasdaq Stock Market . Through Go IPO, the Company services clients by assisting throughout the audit and legal firm hiring process, translating requested documents into English, assisting in the preparation of documentation for internal controls required for an initial public offering or de-SPAC, providing general support services, assisting in the preparation of the S-1 or F-1 filing, and more.As compensation for its services, HeartCore expects to generate from BloomZ an aggregate of $500,000 in initial fees. In addition, HeartCore has received a warrant to acquire 4% of BloomZ's common stock, on a fully diluted basis. "We are very pleased to have signed our sixth and seventh Go IPO deal to start the new calendar year," said CEO Sumitaka Yamamoto. "The pipeline remains robust, as we continue to receive substantial interest from Japanese companies looking to tell their equity story to the U.S. investment community. In addition to the initial cash fee we receive, we expect the value from the warrants we'll be able to recognize from our Go IPO clients will be beneficial to our financials for this year and beyond."

08:33 EST Distribution Solutions announces partnership extension with Criterion Collection - Distribution Solutions, a division of Alliance Entertainment, announced it has extended its partnership with the Criterion Collection, a continuing series of important classic and contemporary films on home video. With this extension, Distribution Solutions continues their distribution of the Criterion Collection's titles in the physical media space across the United States, along with all backroom services including inventory, order management and financial services. "We look forward to continuing our partnership with Criterion," said Ben Means, President of Distribution Solutions. "We take pride in supporting their dedication to distribute their top-shelf catalog to appreciative fans of classic and contemporary films of arthouse cinema and independent filmmaking." On June 23, 2022, Alliance Entertainment announced that it will become publicly listed through a merger transaction with Adara Acquisition Corp.

08:31 EST Hertz announces changes in its Board of Directors - Hertz Global Holdings announced certain changes to the composition of its Board of Directors, effective immediately. Greg O'Hara, founder and Senior Managing Director of Certares and current Chair of the Hertz Board, is stepping down from the Board. Certares and Knighthead were the principals that led Hertz through reorganization. Thomas Wagner, Managing Partner of Knighthead, will remain on the Board as Vice Chair and Colin Farmer, Senior Managing Director at Certares, will continue to stand as Lead Director. Stephen Scherr, CEO of Hertz, will assume the position of Board Chair. Along with this change, Fran Bermanzohn, former Deputy General Counsel at Goldman Sachs, and Jeffrey Nedelman, a Senior Managing Director at Certares, will join the Board as independent directors.

08:30 EST BeiGene announces expansion of coverage on China's NRDL - BeiGene announced that the National Reimbursement Drug List, NRDL, released by China's National Healthcare Security Administration, NHSA, has been updated to include four new indications for its PD-1 inhibitor tislelizumab. KYPROLIS, a proteosome inhibitor licensed-in from Amgen, is included for the first time and XGEVA, a RANKL inhibitor and another Amgen asset, successfully renewed this year. The updated NRDL will officially take effect on March 1, 2023. "The expanded coverage of tislelizumab, new inclusion of KYPROLIS, as well as the renewal of XGEVA on the latest NRDL will allow more patients in China to have access to these high-quality medicines at affordable prices," said Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China, at BeiGene. "After several years of reform, the NHSA has established a basic medical insurance system with universal coverage. Through the annual updates of the NRDL, it made a leap forward in broadening access to innovative oncology medicines across China. At BeiGene, we share this same vision and endeavor to advance global health by making innovative medicines more accessible and affordable to patients in China and globally."

08:26 EST Incannex says independent data review commences for PsiGAD1 trial - Incannex Healthcare announced that the PsiGAD1 clinical trial, designed to assess Incannex's psilocybin-assisted psychotherapy for the treatment of generalised anxiety disorder, has achieved its interim milestone of 29 patients completing primary endpoint assessments. Independent analysis of the interim study data has commenced. Treatment of GAD with currently accepted medications and therapies remains inadequate, with less than half of patients achieving remission. Psilocybin-assisted psychotherapy has shown promise in the treatment of several mental health conditions. PsiGAD1 was developed in collaboration with Dr Paul Liknaitzky, Head of the Clinical Psychedelic Lab at Monash University and a member of the Incannex scientific advisory board. The trial is designed to assess the safety and efficacy of the Company's unique psilocybin program in an active placebo-controlled study. The 10-week treatment program includes two dosing sessions with either psilocybin or active placebo. Safety, efficacy, quality of life, and other aspects of mental and physical health are assessed. To date, 45 participants have been enrolled in the study, with 29 participants having now completed the treatment protocol and main outcome assessment following treatment. The interim analysis of the study data to date, conducted by an independent Data Safety Monitoring Board comprising experts who are not part of the trial, has commenced. The independence of the DSMB is critical to maintain a blinded study and consequent integrity of the final data readout and analysis. Recommendations from the DSMB will be provided in March 2023, at which time the Company will provide another public announcement. The trial continues to progress well and on time, with retention of all participants who have been enrolled. The trial team have identified no safety concerns to date. The interim analysis will allow Incannex to make key decisions on regulatory strategy and, in parallel, planning of pivotal studies, while continuing to collect data from the PsiGAD1 trial. Patient recruitment is ongoing towards fulfilling the complete study cohort of 72 patients.

08:22 EST APA Corp. reports Q4 estimated average realized prices for U.S. oil $84.00 bbl - Reports Q4 estimated average realized prices for international oil $88.00 bbl. Reports Q4 estimated average realized prices for U.S. NGL $25.00 bbl. Reports Q4 estimated average realized prices for International NGL $56.00 bbl. Reports Q4 estimated average realized prices for U.S. natural gas $3.90 Mcf. Reports Q4 estimated average realized prices for International natural gas $4.60 Mcf. Reports Egypt tax barrels 40 MBoe/d. Reports realized loss on commodity derivatives $23M. Reports dry hole costs $75M-$85M. Reports net gains on oil and gas purchase and sales $75M. Reports general and administrative expense $160M.

08:19 EST Entain announces accelerated plans to exit unregulated markets - Entain announces that it has accelerated its plans to exit a number of unregulated markets where it no longer sees a path to domestic regulation. "On 12 November 2020, Entain announced a clear strategy for sustainability, growth and innovation. As part of that strategy, the Group made a commitment that, by the end of 2023, 100% of the Group's revenue would come from markets that are nationally regulated. From today, the Group will accelerate this process by exiting its few remaining markets where there is no clear path to market liberalisation via domestic regulation. The Group is now licensed in more than 30 countries and will remain in only a small number of markets where it expects changes in regulation will enable it to obtain domestic licenses in due course. With the exception of these markets, 100% of the Group's revenue will now be from domestically regulated markets where it is licensed. The net gaming revenue and EBITDA impact from these closures is relatively small and will have no effect on current expectations," the company stated in a notice to the market. Reference Link

08:16 EST Poet Technologies teams with ADVA for highly integrated 4x100G solutions - POET Technologies announced that it has developed multi-engine 100G CWDM4 and 100G LR4 chip-on-board solutions for its lead customer, ADVA Optical Networking SE. ADVA will use POET's multi-engine transmit and receive chips in an innovative pluggable solution that packs the functionality of four independent 100Gbit/s interfaces into a single QSFP-DD housing. "ADVA's MicroMux Quattro brings the industry's smallest aggregation technology all the way to the network core. Engineered as a standard-compliant plug in a QSFP-DD form factor, it fits into a 400Gbit/s socket, enabling it to meet legacy needs. This innovative pluggable solution packs the functionality of four independent 100Gbit/s interfaces or two independent 200Gbit/s interfaces into a single QSFP-DD housing," said Ross Saunders, GM of Optical Engines, ADVA. "POET's unique design of its optical engines with hybrid integration of optical chips and monolithically integrated MUX and DMUX enables us to deliver industry-leading products in a small form factor that is scalable to high volume production as well as to higher data rates, such as 1.6Tbit/s and 3.2Tbit/s, thereby enabling much higher bandwidth in a pluggable form factor." POET has successfully demonstrated 10km operation of 100G LR4 optical engines in its Shenzhen Lab and plans to ship beta samples to ADVA in Q1 2023 with production targeted in the second half of 2023.

08:13 EST SAB Biotherapeutics gets additional $8.2M in funding in closeout DoD contract - SAB Biotherapeutics announced that the company has received an additional $8.2M from the U.S. Department of Defense related to the closeout of the discontinued COVID-19 prototype research and development contract. This brings the total final closeout settlement to $16.8 million received since November 2022. "Our work with the DoD has clinically validated our unique approach and accelerated SAB's novel polyclonal antibody platform to Phase 3 stage of development," said Eddie Sullivan, co-founder, President, and Chief Executive Officer of SAB Biotherapeutics. "We are moving full speed ahead with our Influenza, C. diff. and Type I Diabetes programs and look forward to bringing much needed treatment solutions to patients." Based on its current operating plans and recent developments, SAB now expects cash and cash equivalents, and anticipated cash flows will be sufficient to fund its operating expenses and capital expenditure requirements through 2023.

08:12 EST Lexagene says MiQLab detects Mycoplasma at minute levels - LexaGene Holdings announced news regarding the ability of the MiQLab System to detect Mycoplasma at minute levels. Jack Regan, CEO and Founder of LexaGene commented, "In the process of completing the follow-on feasibility study with one of our biopharma customers, I'm thrilled to report that through this work, we've made an ~500X improvement in sensitivity for Mycoplasma. We've communicated this achievement, plus other development milestones, to our biopharma customers, who have in turn expressed great enthusiasm."

08:11 EST Singing Machine shares vision for future of in-car karaoke experience - The Singing Machine Company shared its vision for the future of fully-integrated, in-car karaoke entertainment last week at CES 2023, and as the Times UK noted, "Long family journeys will never be the same..." One of the world's largest consumer karaoke companies, Singing Machine, attracted the attention of top automotive brands domestically and abroad to demo its new, commercially available in-car karaoke microphone, specially designed to fully integrate with global car manufacturers. Powered by streaming karaoke music giant Stingray's proprietary in-car karaoke app, Singing Machine's latest launch into the automotive karaoke space, will have more than100,000 karaoke music videos, first-of-its-kind safety features, and proprietary technology that allows for unique vocal enhancements such as pitch correction, vocal effects and anti-howling, along with a platform to make future gamification features possible. Singing Machine CEO Gary Atkinson commented, "CES 2023 cemented its position yet again as one of the leading global automotive and mobility trade shows. With the rise of autonomous driving, the demand and offering for expanded entertainment options within cars was overwhelming. In my mind, it is not a question of if, but rather when, karaoke microphones will appear within cars as standard."

08:10 EST Ontrak announces initial assessment results for Wholehealth+ program members - Ontrak announced initial assessment results showing that after six months, 30% of assessed Ontrak Wholehealth+ members sustained a clinically significant reduction in anxiety symptoms and 55% sustained a clinically significant reduction of depressive symptoms. In June 2022 Ontrak Health implemented the widely accepted PHQ-9 and GAD-7 assessments as foundational measurements of its innovative care coaching model and evidence-based Wholehealth+ program. While mostly used by providers, Ontrak Health has incorporated them into its care coaching model to promote better monitoring, collaboration, and accountability with its providers and customers. Thousands of assessments have been completed representing results for more than 1,000 unique program enrollees. Ontrak care coaches perform ongoing reassessments with members at regular intervals so that the scores can be trended and monitored for symptom change. "The inclusion of PHQ-9 and GAD-7 assessments in the Ontrak Wholehealth+ program is an important step in measuring mental health improvements for our members. Regular assessment of members' PHQ-9 and GAD-7 scores can provide valuable insights into our members' progress in mental health care and help our providers tailor treatment plans to meet the specific needs of each member. Providing enrollees with access to and interpretation of their assessment scores over time helps members better identify targeted mental health concerns, leading to greater involvement in their treatment outcomes," noted Judith Feld, MD, MPH, MMM, Chief Medical Officer, Ontrak Health.

08:09 EST Unity Biotechnology reports granting of new employment inducement award - UNITY Biotechnology announced that from January 3, 2023, through January 17, 2023, the Compensation Committee of the Board of Directors granted a new employee a stock-based award covering an aggregate of 900 shares of UNITY common stock, including options to purchase an aggregate of 900 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

08:08 EST Bionano Genomics announces publication of interim readout from OGM trial - Bionano Genomics announced the publication of an interim report from an ongoing clinical trial designed to support establishing OGM as part of standard of care in diagnosis of genetic disease for prenatal subjects. This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows. This prenatal study focuses on comparing OGM to SOC, including concordance, reproducibility, technical success rates, turnaround time, diagnostic yield, and health economics. This first interim readout is designed to evaluate endpoints connected to analytical performance in key areas of technical performance and reproducibility of OGM. The study is an Institutional Review Board-approved, multicenter, double-blinded trial with samples from 123 clinical research subjects analyzed in a total of 200 sample runs to date. All samples had been previously tested with traditional methods like karyotyping, fluorescence in situ hybridization and chromosomal microarray. The samples were from cases with known pathogenic or likely pathogenic variants, cases with known variants of uncertain significance, cases with no known reportable variant and genomic controls. This publication describes OGM performance metrics like robustness and reproducibility from site-to-site, operator-to-operator and run-to-run for the first time ever and for the largest number of prenatal samples investigated with OGM to date. Key findings for the technical endpoints were reported as follows: Results of OGM analysis were comparable, in a single assay, to the results of two separate SOC tests needed to reach a diagnosis in 56% of cases and to three separate SOC tests needed to reach a diagnosis in 19% of cases; Concordance with SOC - 100%; Concordance with SOC for variant calls - 100%; Reproducibility of analytical QC from site-to-site - 100%; Reproducibility of variant calls from site-to-site - 100%. The publication concluded that these results demonstrate high technical performance of the OGM workflow from DNA isolation through data analysis. The authors reported that replicate run performance demonstrates reproducibility of OGM, suggesting it can be adapted and validated. The authors further pointed out that OGM is not limited to structural variant and copy number variation analysis alone but can also resolve repeat expansions greater than 500bp. The authors also cited OGM's ability to run an additional analysis pipeline for the screening of individuals with an expanded allele in the FMR1 gene that could be causative of Fragile X syndrome. Screening for this repeat expansion is currently performed as a separate SOC test. The authors concluded that a single approach, like OGM, can allow genetic laboratories to provide rapid results with a cost-effective solution.

08:07 EST Rigel Pharmaceuticals: NCCN adds REZLIDHIA to clinical practice guidelines - Rigel Pharmaceuticals announced that REZLIDHIA has been added by the National Comprehensive Cancer Network to the latest NCCN Clinical Practice Guidelines in Oncology for acute myeloid leukemia. REZLIDHIA is now included as a recommended targeted therapy for adult patients with relapsed/refractory AML with isocitrate dehydrogenase-1 mutation.

08:06 EST Pasithea announces contract with WuXi STA to produce PAS-004 - Pasithea Therapeutics announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient for Pasithea's macrocyclic, next-generation MEK Inhibitor, PAS-004 . After the completion of the pre-clinical testing and animal toxicology studies, GMP manufacturing is our final major requirement to support the Company's Investigational New Drug application with the U.S. Federal Drug Association , which is expected in the second half of 2023. ..We are delighted to be working with WuXi STA, one of the largest and most well-respected Contract, Development, and Manufacturing Organizations in the world. We remain on track with PAS-004 development and look forward to our IND submission followed by the initiation of our Phase 1 clinical trial," commented Pasithea CEO, Dr. Tiago Reis Marques."WuXi STA has a proven track record of manufacturing success to FDA standards and we believe that their high-quality capabilities will support progression of our drug candidate into the clinic. PAS-004 has already received orphan drug designation from the FDA for neurofibromatosis 1, and we plan to start our phase 1 clinical trial in the second half of 2023," stated Dr. Graeme Currie, Chief Development Officer of Pasithea.

08:05 EST Vail Resorts reports certain ski season metrics for season-to-date ended Jan. 8 - Vail Resorts reported certain ski season metrics for the comparative periods from the beginning of the ski season through January 8, 2023, and for the prior year period through January 9, 2022. The reported ski season metrics are for the Company's North American destination mountain resorts and regional ski areas, including the results of Seven Springs, Hidden Valley and Laurel Mountain in both periods and excluding the results of the Australian ski areas and Andermatt-Sedrun in both periods. The data mentioned in this release is interim period data and is subject to fiscal quarter end review and adjustments. Season-to-date total skier visits were up 12.5% compared to the prior year season-to-date period. Season-to-date total lift ticket revenue, including an allocated portion of season pass revenue for each applicable period, was up 5.3% compared to the prior year season-to-date period. Season-to-date ski school revenue was up 35.6% and dining revenue was up 58.0% compared to the prior year season-to-date period. Retail/rental revenue for North American resort and ski area store locations was up 34.4% compared to the prior year season-to-date period. Commenting on the ski season-to-date, Kirsten Lynch, CEO said, "We are pleased to see the growth across the business. Increased staffing levels relative to the prior year period enabled our mountain resorts to deliver full operations of lifts and mountain terrain and normal operations of important guest experiences such as our restaurants, lodging, ski and ride school, and rental and retail locations, which helped drive a return of ancillary spending. Results season to date for the 2022/2023 North American ski season outperformed results from the comparable prior year period, which were negatively impacted by challenging early season conditions, elevated COVID-19 cases associated with the Omicron variant and staffing-driven capacity constraints in our ancillary businesses. Improved conditions at our Colorado, Utah and Tahoe resorts drove a strong rebound in local guest visitation and the easing of travel restrictions in Canada contributed to a strong rebound in destination visitation at Whistler Blackcomb relative to the prior year period." Lynch continued, "Season-to-date destination guest visitation at our western U.S. resorts was below our expectations, which we believe was negatively impacted by the extreme weather causing resort closures and the airline disruptions that impacted travel across the U.S. during the peak holiday period. Based on our significant base of pre-committed guests through advance commitment pass products, strong conditions across our western resorts, and current lodging booking trends, we believe that a portion of the visitation we originally expected over the holiday period will occur later in the season. As a result of all these factors, we now expect that Resort Reported EBITDA for fiscal year 2023 will be in the lower half of the guidance range issued on September 28, 2022. Our guidance assumes a continuation of the current economic environment, normal weather conditions, no material impacts associated with COVID-19 for the remainder of the 2022/2023 North American and European ski season or the 2023 Australian ski season, and the foreign currency exchange rates as of our original September 2022 guidance."

08:03 EST Clearfield reaches milestone of over 50M ports in-market - Clearfield announced the supplying of over 50 million fiber ports of its craft-friendly, Labor Lite family of Clearview cassettes, FieldShield Assemblies, and YOURx Terminals. This total was bolstered by the company's record-setting deployments in calendar year 2022, with over 8.5M ports supplied during the year. "Success in the fiber broadband market is as much about execution as it is innovation," said Kevin Morgan, Chief Marketing Officer at Clearfield. "At Clearfield, we're dedicated to our customers' success and have prioritized ensuring they have the products and support they need, when they need it, to take their fiber broadband networks as far as they can go. As we address ongoing strong customer demand for broadband, we remain focused on further enhancing capacity and improving our lead times to maintain our momentum in the year ahead."

08:02 EST NeuroBo appoints Joseph Hooker as Interim CEO - NeuroBo Pharmaceuticals announced that it has appointed Joseph Hooker as Interim CEO and President. Hooker's appointment follows Gil Price, M.D.'s decision to retire from his position as President and CEO of NeuroBo. NeuroBo's Board of Directors plans to initiate a candidate search with the assistance of a leading executive search firm to identify Dr. Price's permanent successor. Hooker has served as an independent consultant and advised on an ad hoc basis for leading management consultancies and various pharmaceutical companies with respect to clinical trials, CROs and program management. Previously, Hooker was Sr. Director of Clinical Operations/Program Leader Rare Disease, Oncology for X4 Pharmaceuticals, Inc., where he led a cross-functional global program team, pre-clinical through development and commercialization, including strategic planning, oversight, execution of clinical operations and the management of staff.

07:55 EST United Airlines 'on track' to achieve 2023 leverage target

07:54 EST Zai Lab announces inclusion of QINLOCK, NUZYRA on China's NRDL - Zai Lab announced that the National Reimbursement Drug List released by China's National Healthcare Security Administration has been updated to include both QINLOCK for advanced gastrointestinal stromal tumor patients who have received prior treatment with three or more kinase inhibitors in the all-comer setting, and NUZYRA for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections for intravenous formulation.

07:48 EST Solitario reports results from Spur area in Geyser Gold Zone - Solitario Zinc reports that it has received results from a new high-grade gold area, called Spur, south of the recently announced Geyser Gold Zone. The combined Geyser-Spur Gold Zone represents a significant expansion to the original Geyser high-grade area. The broadened area remains open to expansion in all directions with many peripheral assays pending. It is important to note the Geyser-Spur Gold Zone is more than 4.0 kilometers from our previously announced high-grade Downpour Gold Zone, all of which are a part of Solitario's 33,000-acre land holdings in South Dakota. Also, final Downpour channel sample assay results were received and increased the length of high-grade mineralization in two of the trenches. New surface sampling results, as well as previously reported results can be viewed on the attached Geyser-Spur Zone Map. New sampling highlights include: The new Spur assay results have expanded the footprint of gold mineralization to an area measuring approximately 650 x 225 meters from the previously reported oval-shaped area measuring 225 x 125 meters. Fourteen new select grab surface samples averaged 6.8 grams per tonne gold within the expanded footprint. This new high-grade zone, called Spur, measures approximately 150 x 120 meters. Initial trenching assay results yielded a continuous mineralized zone 24 meters long, averaging 1.11 gpt gold. These results correlated well with the two nearest surface grab rock samples of 1.2 gpt gold, situated to the north, and 0.9 gpt gold sample to the south. Assay results are pending for a much larger area surrounding the Geyser-Spur Zone. At Downpour, 3.0 meters grading 15.4 gpt gold were added to Trench 1 bringing the total length to 36 meters grading 17.6 gpt gold and 3.6 meters grading 25.6 gpt gold were added to Trench 5 bringing the total length to 15.6 meters grading 17.1 gpt gold. Chris Herald, President and CEO of Solitario, stated: "These two new high-grade discoveries, the Geyser and adjacent Spur Zone, display average surface grab sample grades of 28.6 and 6.8 gpt gold, respectively. The combined mineralized surface area now measures 650 x 225 meters and remains open in all directions. We anticipate the Geyser-Spur Zone will continue to expand as we receive new assay results peripheral to these reported samples. It is also very encouraging to see the strong correlation of assay grades between our surface grab samples and our initial trenching results at Geyser-Spur. The first eight three-meter trench samples (a continuous 24-meter trench) averaged 1.1 gpt gold and the two nearest surface samples graded 1.2 and 0.9 gpt gold. At Downpour, our high-grade select surface grab samples also had great correlation with trench samples. We look forward to releasing additional assay results as they become available. Finally, drill hole permitting continues to progress and we are still on schedule for a second quarter 2023 completion date for the Environmental Assessment."

07:46 EST Sarissa Capital Management issues statement on Amarin - Sarissa Capital Management made the following statement on Amarin Corporation: "In 2022 alone, Amarin stock lost over two-thirds of its value, and shareholders lost over $840 million in equity. The European launch is behind schedule, reimbursement in Germany appears imperiled, and spending mismanagement has weakened the cash coffers. Yet the board has the audacity to state publicly, "the Company made solid progress in 2022, against its strategic objectives." To shareholders, the owners of the company, these statements are gravely concerning because they reflect a total lack of understanding of events and the mission of the board and management - to maximize value for shareholders. To do so, the company must not destroy value. Indeed, Amarin has repeatedly overpromised and underdelivered. Below are three of many examples. Vascepa is a great drug with the potential to have a meaningful impact on society. However, since the label expansion for cardiovascular risk reduction, Amarin stock has lost over 90% of its value. Last year, management committed to launching in up to six key European markets and obtain pricing and reimbursement approval in up to eight European markets in 2022. They launched and secured positive pricing and reimbursement decisions in only five European markets... Amarin's slow, reactive responses to changing market dynamics have destroyed significant shareholder capital. An alarming example from 2022 is Amarin's slow response to the US launch of a third generic in January 2022 that quickly and meaningfully reduced sales via both price and volume...As detailed in our previous press release, Sarissa has submitted notice to Amarin to call a special meeting to remove Chairman Per Wold-Olsen from the board and add 7 directors to the board. In accordance with UK law, Amarin has up to 21 days to call the special meeting, which must be held within 28 days of calling the special meeting. We are asking all shareholders to remain engaged and voice their opinions by voting at the special meeting.

07:41 EST JB Hunt falls 5% after Q4 EPS misses consensus estimates - Shares of JB Hunt (JBHT) are down 5% or $8.30 per share to $168 per share, after reporting Q4 EPS that came in less than analyst consensus estimates. Other publicly traded companies in the freight trucking space include Best Inc. (BEST). Knight-Swift (KNX) Schneider (SNDR) and Landstar System (LSTR).

07:40 EST Gibraltar Industries releases annual Corporate Social Responsibility report - Gibraltar Industries released its annual Corporate Social Responsibility report detailing the company's work to improve lives and make a difference in the world. "With this report, we are deepening our commitment and demonstrating our responsibility to our people, our communities and our stakeholders," said CEO Bill Bosway. "As a significant player in creating more sustainable ways to grow food, generate cleaner energy and live and work with greater efficiency, ease and comfort, we are confronting some of the world's most important challenges."

07:37 EST SciSparc gets approval from Soroka to conduct study in children with ASD - SciSparc announced it has been granted an approval by the Soroka University Medical Center o conduct its clinical study for SCI-210 in patients suffering from autism spectrum disorder or ASD. On January 9, SciSparc announced it signed an agreement with Soroka Medical Center to perform its clinical study, led by Prof. Gal Meiri, head of Soroka Medical Center's Preschool Psychiatry Unit. The trial will investigate the effect and safety of SciSparc's drug candidate SCI-210, a proprietary combination of cannabidiol and CannAmide , in comparison to CBD monotherapy in treating ASD. The study's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 in children with ASD in a randomized, double-blind, placebo controlled with cross-over study. The design of the study includes a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial of 60 children. The trial has three primary efficacy end points: the Aberrant Behavior Checklist-Community parent questionnaire; the Clinical Global Impressions-Improvement C performed by a clinician; and the effective therapeutic dose. ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term "spectrum" in autism spectrum disorder refers to the wide range of symptoms and severity.

07:35 EST KemPharm partners with Hypersomnia Foundation - KemPharm announced its partnership with the Hypersomnia Foundation, which engages, informs and champions the global community to improve the lives of people with idiopathic hypersomnia and related sleep disorders. IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness. It is estimated that approximately 37,000 patients are currently diagnosed with IH and seeking treatment, although the total population may be much larger due to patients not seeking treatment or having not been diagnosed. KemPharm is currently investigating KP1077 in a double-blind, placebo-controlled, randomized-withdrawal, dose-optimizing, multi-center Phase 2 clinical trial evaluating the efficacy and safety of KP1077 for the treatment of IH. KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.

07:31 EST PSEG to sell its 25% equity stake in Ocean Wind 1 to Orsted, no terms disclosed - Public Service Enterprise Group has agreed to sell Orsted its 25% equity stake in the Ocean Wind 1 offshore wind energy project, providing Orsted with 100% ownership of the project. Orsted, America's largest offshore wind energy company, will proceed with development of the project with PSEG supporting onshore infrastructure construction. The transaction between Orsted and PSEG is expected to close in the first half of 2023, pending the required closing conditions. The initial delivery of power from Ocean Wind 1 is scheduled for the end of 2024, and full commissioning is expected in 2025.

07:15 EST Idaho Strategic locates greater than 4% Total Rare Earth Oxides - Idaho Strategic Resources announced the locating of surface outcrops with greater than 4% Total Rare Earth Oxides during its 2022 exploration program at Lemhi Pass. In the well-studied Lemhi Pass District, previous state and federal agency work have shown maximum REE assay values as high as 2%. These new IDR sample results are significant because they essentially double the previously known upper end of assay values as published in the USGS, IGS and other references. These latest assays lend validation to our company belief that the Lemhi Pass District is largely underexplored for REE's; since their discovery in the district was ancillary, to the government's search for nuclear related fuels in the 1950's. IDR's Vice President of Exploration, Rob Morgan commented, "Lemhi Pass continues to impress us. It is very encouraging to see samples having half of their total rare earth element content coming from neodymium; located in similar geological settings and covering 1.5 miles in length. Many of our prospects in the area lie on or near the Lemhi Pass Fault, which suggests the district may have some REE mineral zonation associated with this regionally significant fault." The listed samples were gathered from four different prospects within IDR land holdings; and are from the northern part of the Lemhi Pass District. One sample from Prospect #2 assayed 4.26% TREO; with 2.5% of that value contributed from neodymium alone. Likewise, another sample contained 2.35% REE; with 1.21% coming from neodymium. The dominant REE mineral is monazite. Monazite is a phosphate mineral and most of our strongest REE values are associated with phosphorus. This mineral occurs as opaque, subhedral, yellow-green to reddish-brown crystals which are mostly microscopic in size, making it hard to detect with the naked eye. Gangue minerals associated with REE mineralization include quartz, pink microcline, and iron oxides; such as specularite and limonite.

07:14 EST Farfetch announces changes to leadership team - FARFETCH announces changes to its leadership team. Elizabeth von der Goltz has joined the FARFETCH Executive team, taking on the roles of Chief Fashion and Merchandising Officer and CEO of Browns. Sindhura Sarikonda will also join the company this month as President, Americas. Stephanie Simon is also joining the business to head up Community and Web3 efforts for the FARFETCH Group as Vice President Community and Web3. Separately, Chief Brand Officer, Holli Rogers, and Chief Growth Officer, Martin Avetisyan, will be leaving the company to pursue other opportunities.

07:13 EST Orezone Gold sees 2023 gold production 140,000-155,000 ounces - For 2023, the Company forecasts gold production in the range of 140,000 to 155,000 ounces at an all-in sustaining costs of $975 to $1,075 per ounce sold. Capital expenditures are expected to total between $43 to $49 million as the Company invests in growth projects to improve the future cost structure and mine life of the Bombore operation. Patrick Downey, President and CEO commented, "Our 2023 guidance builds on the strong operating performance that we saw in December 2022 and includes a number of important initiatives that will immediately strengthen the long-term value of the mine and position the Company for future growth. The expected strong cash flow in 2023 will contribute to our debt reduction and growth plans. We intend on delivering on our annual goals in a safe and responsible manner, while maintaining our strong community relations as we continue to advance Bombore towards its next stage of expansion."

07:11 EST Benson Hill achieves ProTerra sustainability certification - Benson Hill announced that it became one of the first U.S.-based ingredient providers to achieve the international ProTerra Certification, a global standard that sets the bar for sustainable agricultural practices and labor practices as well as segregated non-GMO programs and more. The ProTerra Certification program promotes social and environmental sustainability through food and feed supply chains, to support efforts to continuously improve day-to-day business operations and to help organizations to engage and implement the concept of sustainable development. Throughout an extensive certification process, Benson Hill completed audits of its Creston, Iowa, and Seymour, Ind., plants as well as two shipping ports that store and transport its non-GMO soymeal. "Through our journey with ProTerra we gained important insights to solidify our position as a global ingredients company focused on responsible growth," said Andres Martin, Executive Vice President and General Manager, International for Benson Hill. "Achieving the ProTerra certification standard is a testament to the ESG principles guiding our work to sustainably deliver our non-GMO soybean portfolio to markets within and outside the United States."

07:09 EST Apollo Silver reports further assay results from Phase 2 drilling at Calico - Apollo Silver reports additional assay results from the recently completed Phase 2 of the 2022 Drill Program at the Calico Silver Project located in San Bernardino County, California. Results include the thickest, highest grade silver intercept reported to date at Calico: 189 g/t silver over 140.5 metres from surface. Bonanza grade silver intercepted in two holes: 1,610 g/t Ag over 1.5 m from 92.5 m downhole, and 1,095 g/t Ag over 1.5 m from 82.0 m downhole. Results for 15 holes are reported below, bringing the total number of holes released for Phase 2 drilling to 31 out of 44. Stantec Consulting Services Ltd. engaged for the 2023 Calico mineral resource estimation update. New significant intercepts include: SILVER: 189 g/t Ag over 140.5 m from surface, including; 416 g/t Ag over 24.0 m from 82.0 m depth down hole, and including 528 g/t Ag over 4.5 m from 82.0 m depth down hole, and 658 g/t Ag over 6.0 m from 92.5 m depth down hole, which includes 1,610 g/t Ag over 1.5 m from 92.5 m depth down hole. 129 g/t Ag over 58.5 m from 1.0 m depth down hole, including; 367 g/t Ag over 6.0 m from 19.0 m depth down hole, and including 421 g/t Ag over 1.5 m from 20.5 m depth down hole, and 597 g/t Ag over 1.5 m from 23.5 m depth down hole. 138 g/t Ag over 112.0 m from surface, including; 539 g/t Ag over 4.5 m from 80.5 m depth down hole, and including 1,095 g/t Ag over 1.5 m from 82.0 m depth down hole. 113 g/t Ag over 43.5 m from 8.5 m depth down hole; 138 g/t Ag over 57.0 m from 5.5 m depth down hole; 115 g/t Ag over 63.0 m from 2.5 m depth down hole; 141 g/t Ag over 74.5 m from surface, including; 311 g/t Ag over 1.5 m from 16.0 m depth down hole. "We are delighted with the results from the 2022 drilling at Calico," commented Apollo's VP Exploration & Resource Development Cathy Fitzgerald. "The design of the 2022 drill program included not only infill drilling, but targeted drilling to define high-angle structures that may have acted as feeder zones for silver mineralization. Our drilling results to date, in combination with historical and new mapping has allowed us to more accurately model controlling structures and identify trends in high-grade silver mineralization. These outstanding results support our understanding of the geological controls on high grade silver mineralization. With the laboratory results coming in at a steady pace, we are in an excellent position to hit the ground running with the resource update work program."

07:05 EST Paratek announces inclusion of NUZRYA in China's NRDL - Paratek Pharmaceuticals (PRTK) announced that China's National Healthcare Security Administration has added the intravenous formulation of NUZYRA to the country's National Reimbursement Drug List for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, resulting in millions of patients gaining access to the broad-spectrum, once daily antibiotic. NUZYRA was granted approval by the U.S. Food and Drug Administration in October 2018 and Paratek initiated the U.S. product launch in February 2019. Paratek's partner in China, Zai Lab Limited(ZLAB) received approval of both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration of China for the treatment of CABP and ABSSSI in December 2021.

07:02 EST EC grants Krystal Biotech orphan designation for KB407 for CF treatment - Krystal Biotech announced that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis or CF. KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene directly to the airway epithelial cells when delivered via a nebulizer. By inducing expression of full length, normal CFTR protein in the lung, treatment with KB407 has potential to restore ion and water flow into and out of lung cells to correct the lung manifestations of the disease in patients regardless of their underlying genetic mutation. "We are pleased that the European Commission has granted orphan drug designation to KB407, which we believe is an important step toward advancing this option to treat patients with CF," said Suma Krishnan, President of Research and Development at Krystal Biotech.The U.S. Food and Drug Administration has also granted Orphan Drug designation for KB407 to treat patients with CF.

07:02 EST Nielsen expands relationship with Netflix - Nielsen has announced an expansion of its relationship with Netflix, which includes a multi-year agreement to provide linear and streaming audience data across the U.S., Mexico and Poland. In the U.S., Netflix will subscribe to Nielsen's National TV measurement data and Streaming Platform Ratings. In Mexico and Poland, Netflix will subscribe to cross-platform audience insights which are derived from streaming panels in each respective market.

07:00 EST Wabash announces 10-year agreement with Ryerson - Wabash has announced a 10-year agreement with Ryerson, a leading value-added processor and distributor of industrial metals. Under this agreement, Ryerson will be a key supplier to Wabash for steel, stainless steel and aluminum products used across Wabash's full portfolio.

06:34 EST Cazoo reports preliminary Q4 UK Retail units sold of around 17,750 - Reports preliminary UK Retail units sold of around 17,750 in Q4 and ~65,000 in FY 2022. Strong sales despite challenging economic backdrop demonstrates strength of offering. Now sold well over 100,000 cars entirely online in the UK in just 3 years since launch.

06:33 EST CGI Inc. adds RISE with SAP to portfolio of services in Canada - CGI (GIB) announced it is strengthening its long-standing global partnership with SAP (SAP) by adding RISE with SAP to its portfolio of services in Canada, which already includes S/4HANA. The RISE with SAP certification enables CGI to accelerate clients' transitions to the cloud. With this new certification, CGI is well positioned to modernize ERP solutions for a broader segment of the market and offer enhanced end-to-end capabilities for its clients, allowing them to focus on their holistic digitization and accelerate business outcomes.

06:32 EST Cazoo targets sale of 40,000-50,000 UK retail units in 2023 - The company said, "Over the past 12 months we have demonstrated our ability to buy and sell cars at significant scale and consolidated our resources on the UK market. Our positive momentum has continued into 2023, and so far in January we have seen solid unit sales and record finance and ancillary attachment rates. However, in the current economic environment we believe the right course of action for 2023 is to focus on further improving our unit economics, reducing our fixed cost base and maximising our cash runway. Our revised FY 2023 plan, approved by the Board of Directors, aims to rapidly improve the unit economics of the business. To enable these improvements, we are resetting our 2023 top line ambitions to 40,000-50,000 UK retail units, allowing us to focus on higher margin and faster moving inventory and to rationalise our operational footprint. Following this reset, we expect Retail unit sales to return to growth in FY 2024 and beyond. In line with the lower unit expectations for 2023 and the current economic climate, we will be making our operational and logistics networks more efficient through the closure of certain of our vehicle preparation centre and customer centre facilities and making further headcount reductions. This plan is in the process of being finalised and we will provide more detailed information at the time of our FY 2022 results. Importantly, this plan is expected to deliver a significant reduction in our cash consumption and continued progress towards our goal of reaching profitability, without the need to raise further external funding over the next 18-24 months. We expect to end 2023 with over GBP 100m of cash and cash equivalents on our balance sheet. The UK used car market is the largest in Europe, worth over GBP 100bn annually. Digital penetration remains materially below almost all other retail sectors and we believe that our market leading platform, brand, team and infrastructure position us well to realise our ambition of achieving a 5% or greater share of the UK used car market over time."

06:31 EST Broadridge extends digital wealth platform partnership with IGM Financial - Broadridge Financial Solutions (BR) announced IG Wealth Management (IGIFF) has signed a multi-year contract extension to IG's use of Broadridge's R.Broker solution, a component of the Broadridge Wealth Platform.

06:01 EST AppTech Payments regains compliance with Nasdaq listing rules - AppTech Payments announced that it has successfully cured the Nasdaq minimum bid price deficiency. Nasdaq has informed AppTech that its Panel has determined to continue the listing of the Company's securities on the Nasdaq Capital Market and is closing the matter. AppTech has regained Nasdaq compliance as it has had a closing bid price of above $1.00 per share for 10 consecutive business days. That requirement was met on January 3.

05:58 EST Merck picks Perceiv AI for inaugural Digital Sciences Studio cohort - Perceiv AI announced that the company has been selected by Merck for the inaugural Merck Digital Sciences Studio cohort, along with eight other early-stage biomedical startups from a pool of 152 applicants. The program started in November to fuel innovative digital technologies for drug discovery and development. MDSS is a collaboration between Merck and the New Jersey Innovation Institute, with investments from the Merck Global Health Innovation Fund, Northpond Ventures, and McKesson Ventures. The accelerator provides direct investment from Merck, access to powerful Azure Cloud computing, and technology support provided by Microsoft for Startups. Additionally, participating companies are provided opportunities to collaborate with discovery and clinical scientists at Merck for pilots, where appropriate.

05:55 EST Jacobs awarded role on London's Capital Program Delivery Partner Contract - Jacobs has secured a position on Transport for London's Capital Program Delivery Partner Contract working with Gardiner and Theobald. TfL will use this contract to procure all project management, construction management and project management office services and resources. TfL estimates the contract will operate for a four-year period, with immediate mobilization. The contract enables TfL's Capital Delivery teams, responsible for the delivery of all major programs and line upgrades across the TfL network, to access agile consultancy support from Jacobs. Initially, Jacobs will support projects including station improvements; asset maintenance; road improvements; line upgrades; systems; healthy streets; commercial development and major engineering projects.